MaxCyte, Inc. 22 May 2024 4867-2449-5548v.1 MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate...
ROCKVILLE, Md., May 22, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading...
MaxCyte, Inc. 20 May 2024 TR-1: Notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the...
MaxCyte, Inc. 14 May 2024 TR-1: Notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the...
MaxCyte Inc on Wednesday reported a jump in its first quarter revenue, which it said was driven by its core business ...
MaxCyte, Inc. 08 May 2024 MaxCyte announces filing of Form 10-Q for the quarterly period ended March 31, 2024 ROCKVILLE, MD, May 8, 2024...
MaxCyte, Inc. 08 May 2024 MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance ROCKVILLE, MD, May 8, 2024...
ROCKVILLE, Md., May 07, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading...
MaxCyte, Inc. 03 May 2024 MaxCyte, Inc. ("MaxCyte" or the "Company") Notice of AGM Rockville, Maryland - May 3, 2024: MaxCyte Inc...
MaxCyte, Inc. 01 May 2024 MaxCyte, Inc. ("MaxCyte" or the "Company") Total Voting Rights ROCKVILLE, MD, May 1, 2024: MaxCyte Inc...
MaxCyte, Inc. 10 April 2024 MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024 ROCKVILLE, MD, April 10, 2024 - MaxCyte...
ROCKVILLE, Md., April 10, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading...
MaxCyte, Inc. 03 April 2024 MaxCyte, Inc. ("MaxCyte" or the "Company") Total Voting Rights and Block Listing Return ROCKVILLE, MD, April...
The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by A ...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.